Tirz research peptide is a synthetic dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist synthesized exclusively for in vitro and preclinical laboratory evaluation. As a precision biochemical tool, it allows researchers to investigate synergistic incretin receptor activation, cell signaling cascades, and metabolic pathways in experimental models.
Tirz research peptide is a synthetic dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist synthesized exclusively for in vitro and preclinical laboratory evaluation. As a precision biochemical tool, it allows researchers to investigate synergistic incretin receptor activation, cell signaling cascades, and metabolic pathways in experimental models.
The tirz research peptide is a 39-amino-acid synthetic peptide engineered to exhibit dual agonist activity at both the GIP and GLP-1 receptors. Structurally derived from the native GIP sequence, it incorporates C-terminal lipidation via a C20 fatty diacid moiety attached through a linker to extend its circulating half-life in non-human test subjects and in vitro culture media. This structural optimization permits sustained receptor binding kinetics without requiring frequent dosage replenishment in experimental setups.
In modern biochemical literature, the tirzepatide research peptide serves as a paradigm for dual-incretin target validation. By simultaneously engaging two distinct G-protein coupled receptor (GPCR) pathways, this compound provides researchers with a novel means of probing cross-talk between pancreatic, hypothalamic, and peripheral tissue signals. All formulations offered by PX1 Research are supplied as lyophilized solid reagents intended strictly for in vitro assays and animal model investigation.
The primary mechanism of action for the tirz research peptide relies on its unbalanced, dual-agonist profile. In vitro receptor binding assays demonstrate that the peptide acts as a full agonist at the GIP receptor while exhibiting biased signaling with reduced potency at the GLP-1 receptor compared to native GLP-1 peptide. This differential activation favors GIP receptor signaling, which downstream preclinical studies suggest modulates lipid metabolism, insulin secretion, and glucagon dynamics differently than selective mono-agonists.
Upon ligand binding, both GIP and GLP-1 receptors activate intracellular adenylate cyclase via Gs protein coupling, triggering an increase in cyclic adenosine monophosphate (cAMP) accumulation. In rodent pancreatic beta-cell models, this intracellular cAMP surge stimulates protein kinase A (PKA) and exchange protein directly activated by cAMP (EPAC2), facilitating glucose-dependent insulin exocytosis. Researchers utilizing our comprehensive research catalog can investigate how this dual signal amplification alters downstream transcriptional networks compared to single-receptor pathways.
Preclinical investigations using rodent models of obesity and type 2 diabetes have yielded substantial data regarding dual GIP/GLP-1 receptor co-agonism. In diet-induced obese (DIO) mice, administration of dual incretin agonists resulted in greater body weight loss, enhanced insulin sensitivity, and superior glycemic control relative to equimolar concentrations of selective GLP-1 receptor agonists. These findings highlight a distinct synergistic interaction between GIP and GLP-1 pathways in central nervous system nuclei regulating energy homeostasis.
Furthermore, tissue-level studies in non-human primate and murine models indicate that GIP receptor signaling modulates adipose tissue perfusion and lipid storage capacity. In hepatic tissue assays, dual-agonist exposure correlates with reduced intrahepatic triglyceride accumulation and down-regulation of lipogenic gene networks. These preclinical observations position the compound as a vital standard for assays evaluating non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction pathways.
To evaluate metabolic pathway responses effectively, laboratory researchers frequently compare dual-acting compounds against single-target standards and emerging multi-receptor constructs. For instance, comparing the dual GIP/GLP-1 mechanism against a single-target semaglutide research peptide allows scientists to isolate the additive contribution of GIP receptor activation on energy expenditure and beta-cell maintenance.
Conversely, newer research models examine triple-agonist constructs like the retatrutide research compound, which incorporates glucagon receptor activation alongside GIP and GLP-1 targets. Early comparative assays reveal that while mono-agonists like the liraglutide laboratory standard establish a baseline for GLP-1 receptor kinetics, dual and triple agonists induce distinct shifts in metabolic rate and receptor internalization dynamics. Investigating these differences remains a primary focus in modern peptide-based metabolic research.
Proper reconstitution is essential to preserve the structural integrity and biological activity of the tirz research peptide. Laboratory protocols mandate that lyophilized peptide vials be allowed to equilibrate to room temperature inside a desiccator prior to opening, minimizing moisture condensation on the cake. Reconstitution should be conducted using sterile, laboratory-grade solvents such as bacteriostatic water (0.9% benzyl alcohol) or sterile phosphate-buffered saline (PBS, pH 7.4).
When introducing the solvent, run the liquid gently down the inner glass wall of the vial rather than shooting it directly onto the lyophilized powder. Gently swirl the vial in a smooth circular motion until completely dissolved; high-shear mechanical agitation or vigorous shaking must be avoided to prevent protein aggregation and peptide denaturation. For detailed volumetric calculations, researchers should refer to our standardized peptide reconstitution guide.
In its lyophilized state, tirz research peptide exhibits robust stability when stored under controlled environment conditions. For long-term preservation (up to 24 months), vials must be maintained at -20°C or -80°C, sealed away from light and humidity. Short-term storage of the dry powder at 2°C to 8°C is acceptable for up to 90 days without measurable degradation.
Once reconstituted into an aqueous solution, the peptide’s stability window narrows significantly. Liquid aliquots should be maintained at 2°C to 8°C and used within 14 to 21 days depending on the vehicle used. Repeated freeze-thaw cycles must be rigorously avoided, as phase transitions induce structural stress and cleavage of the peptide backbone. Researchers requiring high-volume supplies for multi-week protocols can coordinate custom batch allocations through our bulk laboratory supply program.
Given the precise demands of quantitative preclinical research, peptide purity directly impacts experimental reproducibility. PX1 Research subjects every synthesis lot of tirz research peptide to rigorous analytical validation, guaranteeing a minimum purity of 99.0% as confirmed by Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC). HPLC chromatograms verify the absence of truncated sequences, deletion peptides, and chemical impurities.
In parallel, Electrospray Ionization Mass Spectrometry (ESI-MS) is utilized to confirm the exact molecular weight and chemical identity of the peptide against theoretical mass values. Endotoxin contamination—a major confounder in cell culture and animal studies—is systematically measured via the Chromogenic Limulus Amebocyte Lysate (LAL) assay to ensure levels remain strictly under 0.01 EU/mg. Investigators can access verifiable HPLC and MS batch reports directly for every lot shipped.
Securing reliable research materials requires supply chain transparency and strict quality control. PX1 Research manufactures all compounds in state-of-the-art, GMP-compliant facilities located in the United States. Operating out of primary fulfillment hubs in California and Arizona, we maintain immediate inventory availability coupled with same-day dispatch for orders finalized before cut-off times.
Our analytical testing is conducted independently by ISO 17025 accredited testing laboratories to eliminate bias and provide absolute assurance of purity, sequence accuracy, and sterility. By enforcing lot-specific traceability and publishing comprehensive Certificates of Analysis (COAs) for every product, PX1 Research provides institutional, academic, and private laboratories with the consistency required for high-impact biological research.
What is the primary target mechanism of tirz research peptide?
Tirz research peptide functions as a dual agonist at both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors, allowing researchers to study co-agonist incretin signaling.
Is tirz research peptide approved for human administration or clinical use?
No. Tirz research peptide sold by PX1 Research is strictly intended for in vitro, cell culture, and animal model preclinical research. It is explicitly not for human or veterinary diagnostic or therapeutic use.
What purity level is guaranteed for PX1 Research tirz peptide lots?
Every lot of tirz research peptide is certified at ≥99.0% purity, as verified by independent RP-HPLC chromatography and mass spectrometry (ESI-MS) testing.
How is endotoxin content measured and limited in PX1 Research products?
Endotoxin levels are quantified using a validated Chromogenic Limulus Amebocyte Lysate (LAL) assay, ensuring levels remain below 0.01 EU/mg to prevent cellular inflammation in preclinical assays.
What solvent should be used to reconstitute lyophilized tirz peptide?
Laboratory standards recommend reconstituting lyophilized tirz peptide using sterile bacteriostatic water (0.9% benzyl alcohol) or sterile phosphate-buffered saline (PBS, pH 7.4), depending on assay parameters.
How should reconstituted tirz peptide solution be stored?
Reconstituted solutions should be divided into single-use aliquots and stored at 2°C to 8°C for short-term use (up to 14-21 days) or frozen at -80°C for extended preservation. Avoid repeated freeze-thaw cycles.
Does PX1 Research provide a Certificate of Analysis (COA) for every shipment?
Yes. Every batch of tirz research peptide is accompanied by a lot-specific Certificate of Analysis detailing RP-HPLC purity, mass spectrum identity, and endotoxin assay results.
How does tirz research peptide differ structurally from native GIP and GLP-1?
Tirz is a synthetic 39-amino-acid peptide based on the GIP sequence, modified with non-coded amino acids and a C20 fatty diacid acyl chain to enhance receptor stability and extend its half-life in laboratory models.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.